Former Novartis executive director heads up new immuno-oncology startup

Catherine Sabatos-Peyton's last startup was only in operation for about a year before Novartis AG scooped it up for a cool $248 million. Now, after about five years continuing the work of that startup (CoStim Pharmaceuticals) inside of Novartis, including as executive director and head of immune modulation, Sabatos-Peyton is striking out on her own again. Her latest company, Larkspur Biosciences, launched publicly on Tuesday after operating for about two years in stealth to make drugs for colorectal …
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news